人各有“痣”:痣出现这些变化,有恶变的可能!黑色素瘤不能小看

2020-10-02 39健康网 39健康网

黑痣在每个人身上都会出现,如果有细心观察的话就会发现,很多人的脖子后面都长了一颗黑痣。部分人是出生之后就有,而有的人是后期长起来的。人脖子有黑痣,是好是坏?脖子后面有黑痣其实是个很正常的现象,不必太过

黑痣是我们每个人身上都会出现的,有些人身上的黑痣比较多,有些人比较少。黑痣可以生长在脸上、身上,也有很多人会长在脖子后面。

很多人脖子后面会长一颗大黑痣,有人说是“有福气”,有人则认为是“不祥之兆”,真相如何呢?

人脖子有黑痣,是好是坏?

脖子后面出现黑痣是非常正常的现象,在生活中不必太过在意。只要你的黑痣是边缘清晰、表面光滑,且长时间都是维持在同性状、同等大小即可,这多半是局部黑色素堆积所导致的黑痣。

正常人身体的很多部位都会出现黑痣,如果没有疼痛或其他不良症状,且体积也没有太明显的变化,那无需采取任何措施,不会给身体健康带来显着影响。

但是需要注意,有一种黑痣很危险!

这种黑痣就是黑色素瘤,很多人对此不是很熟悉,虽然黑色素瘤的发病率并不是很高,但是它的致死率却非常高,是非常危险的一种皮肤癌。

黑色素瘤在早期表现是正常皮肤上出现黑色损害,或者是原有的黑痣于近期内扩大,色素加深,随着痣的增大,皮肤损害隆起会呈现斑块或者是结节状,也可以呈现菜花状,表面易破溃、出血。周围会出现不规则的色素晕,如皮下组织生长时,则呈皮下结节或肿块。

如何判断身上的痣是否为恶性?

一般情况下,良性的痣是有规则的并且左右对称,如果你身上的痣边缘不规则且左右不对称,则要注意。

如果你的痣在近期形状慢慢发生改变的话,或者是触碰的时候有隐痛感的话,这个时候要引起警惕,很可能是痣要发生恶变了,建议及时去医院检查。

还有就是如果痣的位置长得很特殊,比如手掌心、腰部周围、腋窝等地方,这些位置很容易被触摸到,为了安全起见,可以到医院去咨询一下。看看是否需要切除,有没有病变的风险。

当发现自己身上存在恶性痣的时候,一定要及时进行手术切除,一般情况下,像交界痣、混合痔这种有恶变倾向的黑痣,通常都会建议切除。而对于一些形状不规则、隆起等异常形态的痣也建议切除。

再来聊聊一个问题:长了黑痣能抠吗?

答案是不能,身上的黑痣一定不要去抓挠、抠破。长期对黑痣进行一些不良刺激引起黑痣溃破,非常容易引起感染,长此以往会导致发生恶变的风险大大增加。

还有一些去除黑痣的方法如激光、冷冻等,也会导致发生恶变的风险增加,在生活中需要去除黑痣的话,要选择正规医院,规范的去除黑痣。

黑痣是我们身上会出现的一个正常生理现象,只要黑痣没有出现一些异常变化可以不用管它,反之,一定要重视起来。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680691, encodeId=212716806915a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 17 05:34:31 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487638, encodeId=8351148e63828, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559026, encodeId=f77e15590267d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565035, encodeId=b280156503564, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2021-07-17 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680691, encodeId=212716806915a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 17 05:34:31 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487638, encodeId=8351148e63828, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559026, encodeId=f77e15590267d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565035, encodeId=b280156503564, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2020-10-04 yese
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680691, encodeId=212716806915a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 17 05:34:31 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487638, encodeId=8351148e63828, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559026, encodeId=f77e15590267d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565035, encodeId=b280156503564, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680691, encodeId=212716806915a, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 17 05:34:31 CST 2021, time=2021-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487638, encodeId=8351148e63828, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1559026, encodeId=f77e15590267d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1565035, encodeId=b280156503564, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sun Oct 04 05:34:31 CST 2020, time=2020-10-04, status=1, ipAttribution=)]

相关资讯

NEJM:Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

对于手术后的BRAFV600E或V600K突变III期黑色素瘤患者,Dabrafenib联合Trametinib 治疗可降低患者复发或远端转移风险。

Clin Cancer Res:抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性!

GNAQ/11激活突变,见于>90%葡萄膜黑素瘤患者,可导致包括MAP激酶和YAP在内的致癌途通路组成性激活。多种疗法对其都疗效欠佳。本研究拟明确抗疟疾药氯喹是否可改善这类患者的治疗效果。

Br J Cancer:个子高,这些癌症风险也高!

身高虽然易于测量,但却是一个复杂的表型,由多种生物学和社会学因素所决定。既往研究显示,身高与许多慢性疾病相关,包括心血管疾病和癌症。前瞻性队列研究显示,身高与多个部位癌症的高发病风险密切相关。

PD1+溶瘤病毒,奥源和力公布OrienX010一项黑色素瘤Ib期研究结果

9月19日,来自北京肿瘤医院郭军团队的斯璐教授在CSCO2020大会上报告了重组人GM-CSF单纯疱疹病毒注射液(OrienX010)联合特瑞普利单抗(PD-1单抗)治疗在可完全切除的 III期及IV

Nature: 推波助澜,淋巴系统可保护瘤细胞免于铁死亡,促进癌细胞转移

该研究显示淋巴中的黑素瘤细胞比血液中的黑素瘤细胞经历较少的氧化应激并形成更多的转移。

Lancet oncol:纳武单抗维持高危黑色素瘤术后辅助治疗的长期疗效明显优于伊匹单抗

经过4年随访,证实了在切除的IIIB-C或IV期黑色素瘤患者中,与伊匹单抗相比,纳武单抗具有持续的无复发存活获益,提示纳武单抗具有长期治疗益处。